knowledge -WSS

knowledge

author：Wikipedia 2025-09-29 22:36:40 - browse：448

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

WSS

European regulators recommend Amylyx's ALS drug be rejected

Kaiser's Risant Health gobbled up Geisinger. Who is next?

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

European regulators consider appeal over Amylyx ALS drug

Readout LOUD podcast: Merger Mondays, Ozempic panic

There’s no way to know how good AI health technologies are

Wikipedia

knowledge

entertainment

Apple is now the first public company to be valued at $3 trillion

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

BioMarin wins approval for gene therapy to treat hemophilia A

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Jerome Adams on the need for new antivirals for Covid

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Virginia high school admissions case could be legal follow

Change Healthcare can notify patients about the breach, HHS says

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Akero's treatment for NASH falls short in cirrhosis study

hotspot

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Humana CEO Bruce Broussard to step down in 2024

FDA's Pazdur wants cancer trials to range beyond China alone

Change Healthcare can notify patients about the breach, HHS says

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Ionis drug prevents swelling attacks due to hereditary angioedema

focus

knowledge

focus

hotspot